{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05660395",
            "orgStudyIdInfo": {
                "id": "ADCT-402-107"
            },
            "secondaryIdInfos": [
                {
                    "id": "2021-005209-29",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "ADC Therapeutics S.A.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)",
            "officialTitle": "A Phase 1b Open-Label Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-to-evaluate-the-pharmacokinetics-and-safety-of-loncastuximab-tesirine-in-participants-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-or-high-grade-b-cell-lymphoma-with-hepatic-impairment-lotis"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-08-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-04-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-12-13",
            "studyFirstSubmitQcDate": "2022-12-13",
            "studyFirstPostDateStruct": {
                "date": "2022-12-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-20",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "ADC Therapeutics S.A.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBCL) participants with moderate and severe hepatic impairment."
        },
        "conditionsModule": {
            "conditions": [
                "Diffuse Large B-Cell Lymphoma",
                "High-grade B-cell Lymphoma"
            ],
            "keywords": [
                "Loncastuximab Tesirine",
                "Lymphoma",
                "DLBCL",
                "HGBCL",
                "Hepatic Impairment"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "BASIC_SCIENCE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 56,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm A: Normal Hepatic Function",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive loncastuximab tesirine 0.15 mg/kg once every 3 weeks (Q3W) for two cycles, then 0.075 mg/kg Q3W for subsequent cycles (1 cycle = 21 days).\n\nParticipants who have a toxicity meeting the criteria for dose reduction will have subsequent doses reduced by 50%. If the toxicity recurs, subsequent doses must be reduced by an additional 50%. A maximum of 2 dose reductions are allowed. Participants who have a toxicity meeting the criteria for dose reduction following Cycle 2 will receive the protocol-specified dose of 50% of initiate dose for Cycle 3, i.e., they will not have an additional dose reduction for Cycle 3.",
                    "interventionNames": [
                        "Drug: Loncastuximab Tesirine"
                    ]
                },
                {
                    "label": "Arm B: Moderate Hepatic Impairment",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive loncastuximab tesirine in a standard 3+3 dose-escalation design. Initial dose will be 0.09 mg/kg Q3W for two cycles, then 0.045 mg/kg Q3W for subsequent cycles (1 cycle = 21 days). The highest dose possibly administered will be 0.15 mg/kg Q3W.\n\nParticipants who have a toxicity meeting the criteria for dose reduction will have subsequent doses reduced by 50%. If the toxicity recurs, subsequent doses must be reduced by an additional 50%. A maximum of 2 dose reductions are allowed. Participants who have a toxicity meeting the criteria for dose reduction following Cycle 2 will receive the protocol-specified dose of 50% of initiate dose for Cycle 3, i.e., they will not have an additional dose reduction for Cycle 3.",
                    "interventionNames": [
                        "Drug: Loncastuximab Tesirine"
                    ]
                },
                {
                    "label": "Arm C: Severe Hepatic Impairment",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive loncastuximab tesirine in a standard 3+3 dose-escalation design. Initial dose will be 0.09 mg/kg Q3W for two cycles, then 0.045 mg/kg Q3W for subsequent cycles (1 cycle = 21 days). The highest dose possibly administered will be 0.15 mg/kg Q3W.\n\nParticipants who have a toxicity meeting the criteria for dose reduction will have subsequent doses reduced by 50%. If the toxicity recurs, subsequent doses must be reduced by an additional 50%. A maximum of 2 dose reductions are allowed. Participants who have a toxicity meeting the criteria for dose reduction following Cycle 2 will receive the protocol-specified dose of 50% of initiate dose for Cycle 3, i.e., they will not have an additional dose reduction for Cycle 3.",
                    "interventionNames": [
                        "Drug: Loncastuximab Tesirine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Loncastuximab Tesirine",
                    "description": "Intravenous (IV) Infusion",
                    "armGroupLabels": [
                        "Arm A: Normal Hepatic Function",
                        "Arm B: Moderate Hepatic Impairment",
                        "Arm C: Severe Hepatic Impairment"
                    ],
                    "otherNames": [
                        "Zynlonta",
                        "ADCT-402"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of Participants with Moderate or Severe Hepatic Impairment Who Experience a Dose-Limiting Toxicity (DLT)",
                    "timeFrame": "Day 1 to Day 21 of Cycle 1, where a cycle is 21 days"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Maximum Concentration (Cmax) of Loncastuximab Tesirine and SG3199 in Serum",
                    "timeFrame": "Day 1 up to 1 year"
                },
                {
                    "measure": "Time to Cmax (Tmax) of Loncastuximab Tesirine and SG3199 in Serum",
                    "timeFrame": "Day 1 up to 1 year"
                },
                {
                    "measure": "Area Under the Concentration-time Curve from Time Zero to the Last Quantifiable Concentration (AUClast) of Loncastuximab Tesirine and SG3199 in Serum",
                    "timeFrame": "Day 1 up to 1 year"
                },
                {
                    "measure": "Area Under the Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau) of Loncastuximab Tesirine and SG3199 in Serum",
                    "timeFrame": "Day 1 up to 1 year"
                },
                {
                    "measure": "Area Under the Concentration-time Curve from Time Zero to Infinity (AUCinf) of Loncastuximab Tesirine and SG3199 in Serum",
                    "timeFrame": "Day 1 up to 1 year"
                },
                {
                    "measure": "Apparent Terminal Elimination Half-life (Thalf) of Loncastuximab Tesirine and SG3199 in Serum",
                    "timeFrame": "Day 1 up to 1 year"
                },
                {
                    "measure": "Apparent Clearance (CL) of Loncastuximab Tesirine and SG3199 in Serum",
                    "timeFrame": "Day 1 up to 1 year"
                },
                {
                    "measure": "Apparent Steady-state Volume of Distribution (Vss) of Loncastuximab Tesirine and SG3199 in Serum",
                    "timeFrame": "Day 1 up to 1 year"
                },
                {
                    "measure": "Accumulation Index (AI) of Loncastuximab Tesirine and SG3199 in Serum",
                    "timeFrame": "Day 1 up to 1 year"
                },
                {
                    "measure": "Number of Participants Who Experience an Adverse Event (AE)",
                    "timeFrame": "Up to approximately 3 years"
                },
                {
                    "measure": "Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)",
                    "timeFrame": "Up to approximately 1 year"
                },
                {
                    "measure": "Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Delay",
                    "timeFrame": "Up to approximately 1 year"
                },
                {
                    "measure": "Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Interruption",
                    "timeFrame": "Up to approximately 1 year"
                },
                {
                    "measure": "Number of Participants Who Experience an Adverse Event (AE) Leading to Dose Reduction",
                    "timeFrame": "Up to approximately 1 year"
                },
                {
                    "measure": "Number of Participants Who Experience a Clinically Significant Change from Baseline in Safety Laboratory Values",
                    "timeFrame": "Baseline up to approximately 1 year"
                },
                {
                    "measure": "Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital Signs",
                    "timeFrame": "Baseline up to approximately 1 year"
                },
                {
                    "measure": "Number of Participants Who Experience a Clinically Significant Change from Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status",
                    "timeFrame": "Baseline up to approximately 1 year"
                },
                {
                    "measure": "Number of Participants Who Experience a Clinically Significant Change from Baseline in 12-Lead Electrocardiogram (ECG) Measurements",
                    "timeFrame": "Baseline up to approximately 1 year"
                },
                {
                    "measure": "Overall Response Rate (ORR)",
                    "timeFrame": "Up to approximately 3 years"
                },
                {
                    "measure": "Duration of Response (DOR)",
                    "timeFrame": "Up to approximately 3 years"
                },
                {
                    "measure": "Complete Response (CR) Rate",
                    "timeFrame": "Up to approximately 3 years"
                },
                {
                    "measure": "Progression-Free Survival (PFS)",
                    "timeFrame": "Up to approximately 3 years"
                },
                {
                    "measure": "Relapse-Free Survival (RFS)",
                    "timeFrame": "Up to approximately 3 years"
                },
                {
                    "measure": "Overall Survival (OS)",
                    "timeFrame": "Up to approximately 3 years"
                },
                {
                    "measure": "Number of Participants With Anti-drug Antibody (ADA) Titers to Loncastuximab Tesirine",
                    "timeFrame": "Day 1 up to 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female participants aged 18 years or older\n* Pathologic diagnosis of relapsed (disease that has recurred following a response) or refractory (disease that failed to respond to prior therapy) DLBCL not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma (2016 World Health Organization classification) who have received at least one systemic treatment regimen\n* Measurable disease as defined by the 2014 Lugano Classification\n* Normal hepatic function or hepatic impairment as defined by the National Cancer Institute Organ Dysfunction Working Group hepatic impairment classification:\n\n  * Arm A Normal hepatic function: bilirubin and aspartate aminotransferase (AST) \u2264 upper limit of normal (ULN)\n  * Arm B Moderate hepatic impairment: bilirubin \\> 1.5 \u00d7 to 3 \u00d7 ULN (any AST)\n  * Arm C Severe hepatic impairment: bilirubin \\> 3 \u00d7 ULN (any AST)\n* ECOG performance status 0 to 2 for participants with normal hepatic function. ECOG 0 to 3 for participants with moderate or severe hepatic impairment\n* Adequate organ function\n* Women of childbearing potential (WOCBP)\\* must agree to use a highly effective method of contraception from the time of giving informed consent until at least 10 months after the last dose of study drug. Men with female partners who are of childbearing potential must agree to use a condom when sexually active or practice total abstinence from the time of the first dose until at least 7 months after the last dose of study drug.\n\nExclusion Criteria:\n\n* Previous therapy with loncastuximab tesirine\n* Allogenic or autologous stem cell transplant within 60 days prior to start of study drug (C1D1)\n* Human immunodeficiency virus (HIV) seropositive\n* Serologic evidence of chronic hepatitis B virus (HBV) infection and unable or unwilling to receive standard prophylactic antiviral therapy or with detectable HBV viral load\n* Serologic evidence of hepatitis C virus (HCV) infection without completion of curative treatment or with detectable HCV viral load\n* History of Stevens-Johnson syndrome or toxic epidermal necrolysis\n* Lymphoma with active central nervous system involvement at the time of screening, including leptomeningeal disease\n* Breastfeeding or pregnant\n* Significant medical comorbidities\n* Major surgery, radiotherapy, chemotherapy, or other anti-neoplastic therapy, within 14 days prior to start of study drug (C1D1), except shorter if approved by the Sponsor",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "ADC Therapeutics",
                    "role": "CONTACT",
                    "phone": "954-903-7994",
                    "email": "clinical.trials@adctherapeutics.com"
                }
            ],
            "locations": [
                {
                    "facility": "The Oncology Institute of Hope & Innovation - Lynwood",
                    "status": "RECRUITING",
                    "city": "Lynwood",
                    "state": "California",
                    "zip": "90262",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.93029,
                        "lon": -118.21146
                    }
                },
                {
                    "facility": "Hospital S\u00edrio-Liban\u00eas - Bras\u00edlia",
                    "status": "RECRUITING",
                    "city": "Bras\u00edlia",
                    "zip": "70200-730",
                    "country": "Brazil",
                    "geoPoint": {
                        "lat": -15.77972,
                        "lon": -47.92972
                    }
                },
                {
                    "facility": "Hospital M\u00e3e de Deus - Centro Integrado de Oncologia",
                    "status": "RECRUITING",
                    "city": "Porto Alegre",
                    "zip": "90110-270",
                    "country": "Brazil",
                    "geoPoint": {
                        "lat": -30.03306,
                        "lon": -51.23
                    }
                },
                {
                    "facility": "Hospital S\u00edrio-Liban\u00eas - S\u00e3o Paulo",
                    "status": "RECRUITING",
                    "city": "S\u00e3o Paulo",
                    "zip": "01308-050",
                    "country": "Brazil",
                    "geoPoint": {
                        "lat": -23.5475,
                        "lon": -46.63611
                    }
                },
                {
                    "facility": "A Benefic\u00eancia Portuguesa de S\u00e3o Paulo - Unidade Mirant",
                    "status": "RECRUITING",
                    "city": "S\u00e3o Paulo",
                    "zip": "01323-030",
                    "country": "Brazil",
                    "geoPoint": {
                        "lat": -23.5475,
                        "lon": -46.63611
                    }
                },
                {
                    "facility": "Hospital 9 de Julho",
                    "status": "RECRUITING",
                    "city": "S\u00e3o Paulo",
                    "zip": "01409-002",
                    "country": "Brazil",
                    "geoPoint": {
                        "lat": -23.5475,
                        "lon": -46.63611
                    }
                },
                {
                    "facility": "Albert Einstein Israelite Hospital",
                    "status": "RECRUITING",
                    "city": "S\u00e3o Paulo",
                    "zip": "05652-900",
                    "country": "Brazil",
                    "geoPoint": {
                        "lat": -23.5475,
                        "lon": -46.63611
                    }
                },
                {
                    "facility": "Kyungpook National University Chilgok Hospital",
                    "status": "RECRUITING",
                    "city": "Daegu",
                    "state": "Daegu Gwang'yeogsi",
                    "zip": "41944",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 35.87028,
                        "lon": 128.59111
                    }
                },
                {
                    "facility": "Dong-A University Hospital",
                    "status": "RECRUITING",
                    "city": "Busan",
                    "state": "Gyeongsangnam-do",
                    "zip": "602-812",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 35.10278,
                        "lon": 129.04028
                    }
                },
                {
                    "facility": "Korea University Anam Hospital",
                    "status": "ACTIVE_NOT_RECRUITING",
                    "city": "Seoul",
                    "state": "Seongbuk District",
                    "zip": "02841",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Seoul National University Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi [Seoul-T'ukpyolshi]",
                    "zip": "03080",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "Severance Hospital",
                    "status": "RECRUITING",
                    "city": "Seoul",
                    "state": "Seoul Teugbyeolsi",
                    "zip": "03722",
                    "country": "Korea, Republic of",
                    "geoPoint": {
                        "lat": 37.566,
                        "lon": 126.9784
                    }
                },
                {
                    "facility": "National Taiwan University Hospital",
                    "status": "RECRUITING",
                    "city": "Taipei",
                    "zip": "100",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                },
                {
                    "facility": "Koo Foundation Sun Yat-Sen Cancer Center",
                    "status": "RECRUITING",
                    "city": "Taipei",
                    "zip": "Taiwan 112",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000016393",
                    "term": "Lymphoma, B-Cell"
                },
                {
                    "id": "D000016403",
                    "term": "Lymphoma, Large B-Cell, Diffuse"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "asFound": "B-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18831",
                    "name": "Lymphoma, Large B-Cell, Diffuse",
                    "asFound": "Diffuse Large B-Cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "asFound": "B-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1866",
                    "name": "Diffuse Large B-Cell Lymphoma",
                    "asFound": "Diffuse Large B-Cell Lymphoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000710749",
                    "term": "Loncastuximab tesirine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M347673",
                    "name": "Loncastuximab tesirine",
                    "asFound": "RDT",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}